Lilly to Present at Cambridge Manufacturing Symposium; Competitor Drug Misses 5% Visceral Fat Target
Eli Lilly experts will join SK pharmteco’s April 8 symposium in Cambridge on continuous manufacturing and scalable pharmaceutical processes. Wave Life Sciences’ WVE-007 obesity shot missed its 400 mg visceral fat reduction target of 9.2%, delivering only 5% and sending its shares down 58%.
1. Lilly to Participate in SK Pharmteco Symposium
Eli Lilly will join SK pharmteco’s one-day scientific symposium on April 8 in Cambridge, Massachusetts, focusing on continuous manufacturing, advanced processing and scalable technologies in pharmaceutical production. The event will feature keynote presentations and expert panels aimed at improving efficiency and quality in drug manufacturing processes.
2. Wave’s WVE-007 Obesity Shot Falls Short
Wave Life Sciences reported that its 400 mg dose of WVE-007 achieved less than 1% total fat loss, 5% visceral fat reduction and a 0.2% lean mass loss after three months, missing expectations of 9.2% visceral fat loss. The disappointing data triggered a 58% plunge in Wave’s stock upon market open.
3. Implications for Lilly’s Obesity Franchise and Manufacturing
Wave’s trial failure could leave room for Lilly’s obesity therapies, such as Mounjaro and Zepbound, to strengthen market share. Lilly’s involvement in advanced manufacturing discussions may also enhance its production efficiency and support scalable rollout of high-demand drug candidates.